

Minutes of the Meeting of the Welsh Health Specialised Services Committee

held on 15 May 2018
at Health and Care Research, Castlebridge 4,
Cowbridge Road East, Cardiff

Members Present

Vivienne Harpwood	(VH)	Chair
Carole Bell	(CB)	Director of Nursing and Quality Assurance, WHSSC
Stuart Davies	(SD)	Director of Finance, WHSSC
Charles Janczewski	(CJ)	Independent Member/Chair of the WHSSC Quality and Patient Safety Committee
Sian Lewis	(SL)	Managing Director, WHSSC
Steve Moore	(SM)	Chief Executive, Hywel Dda UHB (part meeting)
Tracy Myhill	(TM)	Chief Executive, Abertawe Bro Morgannwg UHB
Len Richards	(LR)	Chief Executive, Cardiff and Vale UHB
Carol Shillabeer	(CS)	Chief Executive, Powys THB
Jennifer Thomas	(JT)	Medical Director, WHSSC
Chris Turner	(CT)	Independent Member/Audit Lead
Allison Williams	(AW)	Chief Executive, Cwm Taf UHB
John Williams	(JW)	Associate Member/Chair of the Welsh Clinical Renal Network

Apologies

Gary Doherty	(GD)	Chief Executive, Betsi Cadwaladr UHB
Steve Ham	(SH)	Chief Executive, Velindre NHS Trust
Ian Langfield	(IL)	Acting Director of Planning, WHSSC
Judith Paget	(JP)	Chief Executive, Aneurin Bevan UHB
Lyn Meadows	(LM)	Vice Chair

In Attendance

Luke Garthwaite	(LG)	Graduate Trainee
Glyn Jones	(GJ)	Director of Finance, ABUHB (on behalf of Judith Paget)
Julie Keegan	(JK)	Assistant Director of Commissioning, CTUHB
Christopher Markall	(CM)	Senior Finance Manager, CVUHB
Evan Moore	(EM)	Executive Medical Director, BCUHB (on behalf of Gary Doherty)
Claire Nelson	(CN)	Acting Assistant Director of Planning, WHSSC (on behalf of Ian Langfield)
Cath O'Brien	(COB)	Director of the Welsh Blood Service (part meeting)
Matthew Richards	(MR)	Database Developer, WHSSC (part meeting)

Kevin Smith (KS) Committee Secretary and Head of
Corporate Services, WHSSC

Sandra Tallon (ST) Head of Information, WHSSC (part
meeting)

Minutes:

Cathie Steele (CES) Corporate Governance Manager, WHSSC

The meeting opened at 09:30hours

JC18/016	<p>Welcome, Introductions and Apologies The Chair formally opened the meeting and welcomed members.</p> <p>Apologies were noted as above.</p>
JC18/017	<p>Declarations of Interest There were no declarations to note. The Joint Committee noted the standing declarations.</p>
JC18/018	<p>Accuracy of Minutes of the meeting held 27 March 2018 The Joint Committee approved the minutes of the meeting held on 27 March 2018 as an accurate record subject to the following:</p> <ul style="list-style-type: none"> • “Len Richardson” be amended to “Len Richards”; • Amend the health board for Hayley Thomas from Aneurin Bevan UHB (ABUHB) to Powys THB (PTHB). <p>Action: Committee Secretary</p>
JC18/019	<p>Action Log and Matters Arising The Joint Committee received the action log and noted the following updates:</p> <p>JC17/084 AAC Evaluation SL reported that this item was included within the Managing Director’s Report.</p> <p>Neurosciences Strategy SL reported that this report would be presented to a future Joint Committee meeting.</p> <p>Neonatal Workforce Model SL reported that a letter had been sent to the Neonatal Network and a reply was awaited.</p> <p>High Cost Drugs AW provided the Joint Committee with an update, noting that the Chief Executives would discuss the item at the all Wales Chief Executive’s meeting.</p> <p>SL noted that she has raised and discussed this with the Chief Medical Officer at Welsh Government.</p> <p>SD reported that a joint presentation, on the adoption of the new NICE guidelines around high cost drugs, had been given to the all Wales Medicines Strategy Group.</p> <p>Action Log</p>

	<p>CJ noted that the action log did not contain updates on the items and expected completion dates. KS reported that the usual practice was to review outstanding actions in Corporate Directors Group catch up meetings ahead of JC meetings; however this sometimes didn't happen due to other pressures. KS undertook to use best endeavours to address this ahead of future JC meetings.</p> <p>Action: KS</p> <p>Matters Arising There were no matters arising.</p>
JC18/020	<p>Report from the Chair The Joint Committee received an oral report from the Chair.</p> <p>The Chair reported that she had visited the Rutherford Cancer Centre, Newport where PPI were undertaking Proton Beam Therapy.</p> <p>She also reported that she had attended an Individual Patient Funding Request (IPFR) training day, led by All Wales Therapeutics and Toxicology Committee. She provided feedback on a number of points arising from the day including:</p> <ul style="list-style-type: none"> • The findings of the random review of cases, noting that there was continuing inconsistency in IPFR decision-making • Engagement of clinicians in England with the agreed process was sometimes poor. <p>The Joint Committee discussed further mechanisms to engage with clinicians in England.</p>
JC18/021	<p>Report from the Managing Director The Joint Committee received the report of the Managing Director.</p> <p>SL drew attention to the following items within the report which the Joint Committee discussed further:</p> <ul style="list-style-type: none"> • Bariatric Surgery. Performance had improved but expected demand hadn't been experienced. • Cystic Fibrosis. The Joint Committee discussed receipt of in-year business cases and the need to consider the prioritisation process so that it would not be on a first come first funded basis. • Inherited Bleeding Disorders. The Project Board had asked the WHSS Team to make ABMUHB and CVUHB aware of specific concerns. • Major Trauma. The Joint Committee recommended a Memorandum of Agreement be developed with EASC to ensure clarity on responsibilities. <p><i>09:56 Steve Moore joined the meeting</i></p>

	<ul style="list-style-type: none"> • Thrombectomy. The Joint Committee discussed the current capacity, provision and resources, the difficulty experienced accessing current provision, repatriation back to referring hospital following treatment and the impact of the NHS England commissioning requirements • Assisted Automated Communication (AAC). Welsh Government had identified funding and a workshop had been arranged.
JC18/022	<p>Informatics Demonstration</p> <p>The Joint Committee received a presentation from Sandra Tallon (ST), Head of Information and Matthew Richards (MR), Database Developer.</p> <p>In the presentation ST and MR noted the:</p> <ul style="list-style-type: none"> • Source and number of datasets received. • Use of the Commissioning Intelligence Portal and WHSSC Information Systems • Ability within the new system to manipulate and extract data for use within reports • Heat map function which highlights the source of activity • Steps taken to reduce the number of incomplete datasets <p><i>Cath O'Brien joined the meeting</i></p> <p>The Joint Committee discussed the development of the database further noting the:</p> <ul style="list-style-type: none"> • Ability for use within the LHBs and the ability to use to match the utilisation plan against the needs analysis. • Planned engagement with Management Group. • Link with the quality portal. <p>The Chair thanked ST and MR for the interesting presentation.</p>
JC18/023	<p>Advanced Therapy Medicinal Products: Enabling Delivery within NHS Wales and Cell and Gene Therapy</p> <p>The Joint Committee received the Advanced Therapy Medicinal Products: Enabling Delivery within NHS Wales and Cell and Gene Therapy report.</p> <p>In introducing the report, Cath O'Brien (COB), Director of the Welsh Blood Service noted the:</p> <ul style="list-style-type: none"> • Successful bid to have an Advanced Therapy Centre in Wales in collaboration with Birmingham and the plan to develop a Statement of Intent. • Development of clinical pathways and training • Public engagement and perception of these therapies

	<ul style="list-style-type: none"> • Three products recently approved by NICE as technical appraisals. • Oversight steering group (Innovate UK) • Explanation of the first product to be developed • Learning so far. <p>The Joint Committee discussed the report and noted the:</p> <ul style="list-style-type: none"> • Joint work with the All Wales Medicines Strategy Group (AWMSG) and economics to understand financial impacts. • Emerging sector and the approaches internationally. • Need to manage expectations (public and clinical). • Ability to maintain JACIE accreditation of CVUHB facilities. • Standards of the facilities that some companies required. • Financial implications. <p>The Joint Committee agreed to receive a further report at a future meeting. The Joint Committee supported nominations from each LHB to support this work and recommended that correspondence with Judith Paget (JP), Chief Executive of Aneurin Bevan UHB in her role as Chair of the all Wales Chief Executive group. The Joint Committee agreed that NICE recommendations on Advanced Therapy Medicinal Products be used at the early stages of this work.</p> <p>The Joint Committee resolved to:</p> <ul style="list-style-type: none"> • Note the information presented within the report • Support the WHSSC led commission of ATMPs • Note the relationship between JACIE accreditation of the CVUHB BMT unit and the ability of Wales to deliver future NICE approved AMTPs.
JC18/024	<p>Integrated Commissioning Plan 2018-21: Work plan</p> <p>The Joint Committee received the Integrated Commissioning Plan 2018-21: work plan.</p> <p>Claire Nelson (CN), Acting Assistant Director of Planning introduced the report, noting the three schemes scrutinised by the Management Group. The Joint Committee recommended that Management Group undertake scrutiny on all schemes.</p> <p>CN agreed to share an overview that included the key milestones with CJ, outside of the meeting, to provide assurance.</p> <p>Action: CN</p> <p>Members resolved to:</p>

	<ul style="list-style-type: none"> • Approve the processes, roles and responsibilities for implementing the WHSSC Integrated Commissioning Plan 2018-21.
JC18/025	<p>Proton Beam Therapy Update</p> <p>The Joint Committee received the Proton Beam Therapy Update report.</p> <p>SL introduced the report drawing the Joint Committee’s attention to the new providers coming on line in the year shown in table 3. She provided further detail to support the table.</p> <p>Members resolved to:</p> <ul style="list-style-type: none"> • Note the NHS England PBT programme timeline for transition from an overseas to an NHS service; • Note WHSSC’s process and timeline for commissioning PBT from UK providers; • Note that NHS Wales will continue to refer via the UK Proton Clinical Reference Panel; • Note some patients may require treatment overseas during the transition to the NHS service depending on capacity and the complexity of the treatment required; • Note the evidence base has progressed and new indications for medulloblastoma are currently being considered by NHS England; and • Note the savings from the significant cost advantages associated with commissioning PBT from NHS and European providers, are expected to be sufficient to absorb growth and new indications over 2018/19.
JC18/026	<p>Integrated Performance Report</p> <p>The Joint Committee received the Integrated Performance Report.</p> <p>CN noted that an updated report with the March position was available and that the performance had improved at the end of March 2018.</p> <p>The Joint Committee requested that Management Group review the tolerances.</p> <p>Action: IL</p> <p>Members resolved to:</p> <ul style="list-style-type: none"> • Note February performance and the action undertaken to address areas of non-compliance.

JC18/027	<p>Financial Performance Report</p> <p>The Joint Committee received the Financial Performance Report.</p> <p>SD reported that the financial position reported at Month 12 for WHSSC was a forecast overspend to year-end of £4,451k. The deterioration in the year-end position of £2,606k included deterioration against the English provider position reported in Non-Welsh SLAs and IPFR. He noted that no concerns with the accounts had been raised in the Wales Audit Office.</p> <p>The Joint Committee discussed the:</p> <ul style="list-style-type: none"> • Risk associated with HRG4+ and the impact. • The ongoing trend in the use of ICDs. CN reported that a paper on this would be presented to Management Group in the near future. <p>The Joint Committee resolved to:</p> <ul style="list-style-type: none"> • Note the current financial position and forecast year-end position. • Note the residual risks for the year including the HRG4+ risk.
JC18/028	<p>Reports from the Joint Sub-Committees</p> <p>Quality and Patient Safety Committee The Joint Committee received the report.</p> <p>CJ reported that new Independent Members representatives from the LHBs were required to ensure that future meetings were quorate and well attended. The CEOs present agreed to assist with seeking additional members from within their LHB for the Committee. The Chair also agreed to highlight the issue at the all Wales Chairs Meeting.</p> <p>Action: CEOs Action: Chair</p> <p>IPFR The Joint Committee received the report.</p> <p>Audit Committee The Joint Committee received the report.</p> <p>Chris Turner (CT), Independent Member and Chair of the Audit Committee reported that the committee had received the WHSSC Corporate Risk and Assurance Framework (CRAF), which had allowed the committee to receive the assurance it had been seeking.</p>

	<p>All Wales Gender Identity Partnership Group The Joint Committee received the report.</p> <p>Tracy Myhill (TM), Chief Executive of Abertawe Bro Morgannwg UHB and Chair of the Partnership Group noted the slow progress to implement the pathway and new service. She noted receipt of a business case for the all Wales Gender Identity Clinic; however, difficulty had been encountered with the Primary Care aspect of the pathway. The Joint Committee discussed the difficulties and the level of enhanced service (Local Enhanced Service or Directed Enhanced Service). The Joint Committee agreed that a formal letter be sent to Francis Duffy, Welsh Government.</p>
JC18/029	<p>Any Other Business</p> <p>The Committee Secretary confirmed that a forward work plan was maintained for the committee and that the Corporate Risk Assurance Framework and associated risk register was scheduled to come to the committee every six months.</p>
JC18/030	<p>Date and Time of Next Meeting</p> <p>The Joint Committee noted the date of the next meeting as the 10 July 2018.</p>

The meeting concluded at 12:00hours.

Chair's Signature:

Date: